Astragaloside attenuates the progression of prostate cancer cells through endoplasmic reticulum stress pathways

Tan,Bo; Jia,Renfeng; Wang,Gang; Yang,Jinhui

doi:10.3892/ol.2018.9071

Astragaloside attenuates the progression of prostate cancer cells through endoplasmic reticulum stress pathways

Authors:
- Bo Tan
- Renfeng Jia
- Gang Wang
- Jinhui Yang
View Affiliations

Affiliations: Department of Urology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China
Published online on: July 4, 2018 https://doi.org/10.3892/ol.2018.9071
Pages: 3901-3906

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Astragaloside (As) has been demonstrated extensively to serve roles in a variety of tumor types, including glioma, lung cancer, colorectal cancer, breast cancer and cervical cancer, and has therefore been widely used in Traditional Chinese Medicine. To the best of our knowledge, the present study was the first to investigate the efficacy of the Traditional Chinese Medicine astragaloside on tumor growth and the apoptosis of prostate cancer cells. In addition, further investigation into the underlying molecular mechanisms via the endoplasmic reticulum (ER) stress pathway was also performed. In the present study, the human prostate cancer DU‑145 cell line was employed as an experimental model in vitro and cells were divided into five treatment groups: Dimethyl sulfoxide (DMSO) group (control), low‑dose astragaloside group (L‑As; 20 nmol/l), moderate‑dose astragaloside group (M‑As; 50 nmol/l), high‑dose astragaloside group (H‑As, 100 nmol/l) and ER stress suppressor group (tauroursodeoxycholic acid; TUDCA). The proliferative ability and apoptosis rate of the DU‑145 cells were detected via Cell Counting kit‑8 methods and flow cytometry, respectively. Furthermore, the ER stress factors [binding immunoglobulin protein (BiP), C/EBP homologous protein (CHOP) and caspase‑12] were assessed through reverse transcription polymerase chain reaction. Additionally, the protein expression levels of inositol‑requiring enzyme 1 (IRE1), phosphorylated protein kinase R‑like ER kinase (p‑PERK), iron‑regulated transcriptional activator Aft (AFT)4 and AFT6 were measured detected by western blot analysis. Administration of As significantly reduced the cell viability and promoted apoptosis (P<0.05) in a dose‑dependent manner. Expression of ER‑stressed genes BiP, CHOP and caspase‑12 mRNA was increased by As administration, while TUDCA treatment led to a lower mRNA expression of these genes, compared with the control group. Results of western blot analysis indicated that the protein expression of IRE1, AFT4 and AFT6 was upregulated in the H‑As group, and that the ratio of p‑PERK/PERK was also higher than in the other groups. The administration of As demonstrated significant therapeutic effects on the proliferation of prostate cancer cells, as well as the expression of related proteins and genes. The results of the present study suggested future clinical potential of As for the treatment of prostate cancer.

View Figures

View References

1	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
2	Nyquist MD and Dehm SM: Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Horm Cancer. 4:61–69. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hamid AR, Hoogland AM, Smit F, Jannink S, van Rijt-van de Westerlo C, Jansen CF, van Leenders GJ and Verhaegh GW: The role of HOXC6 in prostate cancer development. Prostate. 75:1868–1876. 2015. View Article : Google Scholar : PubMed/NCBI
4	Crawford ED, Stone NN, Evan YY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER and Keane TE: Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 83:664–669. 2014. View Article : Google Scholar : PubMed/NCBI
5	Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR and Ruddon RW: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 10:3919–3926. 2004. View Article : Google Scholar : PubMed/NCBI
6	Victorson DE, Brucker PS, Bode RK, Eton DT, Talcott JA, Clark JA, Knight SJ, Litwin MS, Moinpour CM, Reeve BB, et al: Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 32(26): e25–e31. 2014.
7	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, et al: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384:2027–2035. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
9	Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, Levin K, Kim JH, Peabody J, Siddiqui F, et al: Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 89:268–276. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wang S, Tang L and Chen F: Astragaloside III from Astragalus membranaceus antagonizes breast cancer growth. AJTCAM. 12:183–186. 2015. View Article : Google Scholar
11	Li B, Wang F, Liu N, Shen W and Huang T: Astragaloside IV inhibits progression of glioma via blocking MAPK/ERK signaling pathway. Biochem Biophys Res Commun. 491:98–103. 2017. View Article : Google Scholar : PubMed/NCBI
12	Dai PC, Liu DL, Zhang L, Ye J, Wang Q, Zhang HW, Lin XH and Lai GX: Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6. Tumour Biol. 39:10104283176975552017. View Article : Google Scholar : PubMed/NCBI
13	Yongping M, Zhang X, Xuewei L, Fan W, Chen J, Zhang H, Chen G, Liu C and Liu P: Astragaloside prevents BDL-induced liver fibrosis through inhibition of notch signaling activation. J Ethnopharmacol. 169:200–209. 2015. View Article : Google Scholar : PubMed/NCBI
14	Huang X, Tang L, Wang F and Song G: Astragaloside IV attenuates allergic inflammation by regulation Th1/Th2 cytokine and enhancement CD4+ CD25+ Foxp3 T cells in ovalbumin-induced asthma. Immunobiology. 219:565–571. 2014. View Article : Google Scholar : PubMed/NCBI
15	Chen Y, Gui D, Chen J, He D, Luo Y and Wang N: Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol Biochem. 33:1975–1987. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhao Y, Li Q, Zhao W, Li J, Sun Y, Liu K, Liu B and Zhang N: Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium. J Ethnopharmacology. 169:210–218. 2015. View Article : Google Scholar
17	Wang ZS, Xiong F, Xie XH, Chen D, Pan JH and Cheng L: Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrol. 16:442015. View Article : Google Scholar : PubMed/NCBI
18	Cao SS and Kaufman RJ: Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Sign. 21:396–413. 2014. View Article : Google Scholar
19	Gardner BM, Pincus D, Gotthardt K, Gallagher CM and Walter P: Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb Perspect Biol. 5:a0131692013. View Article : Google Scholar : PubMed/NCBI
20	Deegan S, Saveljeva S, Gorman AM and Samali A: Stress-induced self-cannibalism: On the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci. 70:2425–2441. 2013. View Article : Google Scholar : PubMed/NCBI
21	Liu KC, Yen CY, Wu RS, Yang JS, Lu HF, Lu KW, Lo C, Chen HY, Tang NY, Wu CC and Chung JG: The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cell. Environ Toxicol. 29:428–439. 2014. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hetz C: The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 13:89–102. 2012. View Article : Google Scholar : PubMed/NCBI
24	Tabas I and Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 13:184–190. 2011. View Article : Google Scholar : PubMed/NCBI
25	Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL and McConkey DJ: Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 65:11510–11519. 2005. View Article : Google Scholar : PubMed/NCBI
26	Zou P, Zhang J, Xia Y, Kanchana K, Guo G, Chen W, Huang Y, Wang Z, Yang S and Liang G: ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer. Oncotarget. 6:5860–5876. 2015. View Article : Google Scholar : PubMed/NCBI
27	Cheng X, Gu J, Zhang M, Yuan J, Zhao B, Jiang J and Jia X: Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway. Int Immunopharmacol. 23:304–313. 2014. View Article : Google Scholar : PubMed/NCBI
28	Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, Kast J, Galehdar Z, Palmisano V, Patenge N, Berg D, et al: Parkin is transcriptionally regulated by ATF4: Evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ. 18:769–782. 2011. View Article : Google Scholar : PubMed/NCBI
29	Zhao Y, Li Q, Zhao W, Li J, Sun Y, Liu K, Liu B and Zhang N: Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium. J Ethnopharmacol. 169:210–218. 2015. View Article : Google Scholar : PubMed/NCBI
30	Liu ZW, Zhu HT, Chen KL, Dong X, Wei J, Qiu C and Xue JH: Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovasc Diabetol. 12:1582013. View Article : Google Scholar : PubMed/NCBI
31	Jheng JR, Ho JY and Horng JT: ER stress, autophagy and RNA viruses. Front Microbiol. 5:3882014. View Article : Google Scholar : PubMed/NCBI